Unité de Recherche et d'Innovation, Centre Hospitalier Esquirol, Limoges, France; Inserm U1094, IRD U270, Université Limoges, CHU Limoges, EpiMaCT - Epidémiologie des maladies chroniques en zone tropicale, Institut d'Epidémiologie et de Neurologie Tropicale, OmegaHealth, Limoges, France.
Département de Rhumatologie et Centre de la Douleur, Centre Hospitalier Universitaire, Limoges, France.
Neuromodulation. 2022 Jun;25(4):624-632. doi: 10.1016/j.neurom.2021.12.015. Epub 2022 Feb 26.
Fibromyalgia is a chronic painful condition without real, effective treatment. The administration of repetitive transcranial magnetic stimulation (rTMS) has been shown to have a therapeutic effect on pain, but there are still questions about the maintenance of its effect over time. Continuation of the treatment upon clinical response through maintenance sessions is promising and merits further exploration.
We conducted a randomized, parallel-group, controlled study involving 78 patients to evaluate the effect of rTMS vs sham stimulation after a three-week induction treatment and six months of maintenance treatment (three-week periodicity) on 22 patients who presented a clinical response to the induction treatment. The clinical response was defined as a ≥30% decrease of the baseline visual analog scale (VAS) for pain and a score for the Patient Global Impression of Change (PGIC) >5. The clinic global impression, fibromyalgia impact questionnaire, symptom severity score, and Beck's depression inventory were also studied.
A significant clinical response to treatment with rTMS was observed after the induction phase and maintained over six months, particularly as measured by the PGIC parameter of pain, as well as of the intensity of fatigue and depression, with an absence of adverse effects induced by this method.
A three-week rTMS treatment, characterized by a reduction in pain, as evaluated by VAS, should be continued with the administration of rTMS maintenance sessions for an additional six months to maintain the best possible long-term effects.
纤维肌痛是一种慢性疼痛疾病,目前尚无真正有效的治疗方法。重复经颅磁刺激(rTMS)的应用已被证明对疼痛具有治疗作用,但关于其疗效随时间的维持仍存在疑问。通过维持治疗继续治疗以保持临床疗效是有前途的,值得进一步探索。
我们进行了一项随机、平行组、对照研究,纳入了 78 名患者,以评估 rTMS 与假刺激在诱导治疗 3 周后和维持治疗 6 个月(3 周周期性)对 22 名对诱导治疗有临床反应的患者的疗效。临床反应定义为疼痛的基线视觉模拟量表(VAS)下降≥30%,患者总体印象变化(PGIC)评分>5。还研究了临床总体印象、纤维肌痛影响问卷、症状严重程度评分和贝克抑郁量表。
在诱导阶段后观察到 rTMS 治疗的显著临床反应,并在 6 个月内保持,特别是通过 PGIC 疼痛参数、疲劳和抑郁强度来衡量,且该方法无不良作用诱导。
rTMS 治疗 3 周,表现为疼痛减轻,如 VAS 评估所示,应继续进行 rTMS 维持治疗,再进行 6 个月,以保持最佳的长期效果。